MAPT and Alzheimer disease: Yet, recently promising results have demonstrated that blood p-tau181 is able to predict tau and βA pathologies and to differentiate AD from other neurodegenerative disorders [9], hence supporting this body fluid as a useful source for AD biomarker investigations, aiming to develop simple, accessible, and scalable tests for screening and diagnosis of AD.